Reactions of eosinophilic granulocytes in the sputum and peripheral blood of children suffering from bronchial asthma with signs of eosinophilic and non-eosinophilic inflammation of the bronchi by Koloskova, O. K. et al.
 Regul. Mech. Biosyst., 8(1) 15
 
Regulatory Mechanisms 
in Biosystems 
ISSN 2519-8521 (Print) 
ISSN 2520-2588 (Online)
Regul. Mech. Biosyst., 8(1), 15–18
doi: 10.15421/021703 
Reactions of eosinophilic granulocytes in the sputum  
and peripheral blood of children suffering from bronchial asthma with signs  
of eosinophilic and non-eosinophilic inflammation of the bronchi  
O. K. Koloskova, T. M. Bilous, M. V. Dikal, U. V. Lomakina, T. G. Kopchuk, T. O. Lobanova  
Bukovinian State Medical University, Chernivtsi, Ukraine  
Article info 
Received 19.12.2016 
Received in revised form 
03.02.2017 
Accepted 07.02.2017 
 
Bukovinian State Medical 
University, Teatralna Square, 2, 
Chernivtsi, 58002, Ukraine 
Tel.: +38-050-221-35-16 
E-mail:  
koloskov-elena@yandex.ru,  
bilous.tetiana@bsmu.edu.ua,  
vitmar888@mail.ru 
Koloskova, O. K., Bilous, T. M., Dikal, M. V., Lomakina, U. V., Kopchuk, T. G., & Lobanova, T. O. (2017). 
Reactions of eosinophilic granulocytes in the sputum and peripheral blood of children suffering from bronchial 
asthma with signs of eosinophilic and non-eosinophilic inflammation of the bronchi. Regulatory Mechanisms in 
Biosystems, 8(1), 15–18. doi: 10.15421/021703  
The aim of research was to improve the management of bronchial asthma in children by examining the peculiarities 
and diagnostic value of reaction markers of eosinophil granulocytes in the sputum and peripheral blood of patients with 
signs of eosinophil and non-eosinophil phenotypes of this disease. A cohort of 118 school-age children suffering from 
BA was examined during a period free from attacks. Group I (the main group ) included 61 schoolchildren with signs of 
eosinophil phenotype (EP) of asthma detected by the character of bronchial inflammation with eosinophil granulocytes 
present in the sputum at a level of >3%, group II (the comparison group) included 57 patients with a lower number of 
eosinophils in the sputum (non-eosinophil phenotype (NP) of BA). The average index of the relative content of 
eosinophils in the peripheral blood among the representatives of group I was 5.82 ± 0.63%, and in children with the 
signs of NPBA – 6.02 ± 0.74% (P > 0.05), and average indices in the groups of absolute eosinophil number in the blood 
were 0.37 ± 0.04 and 0.41 ± 0.05 respectively (P > 0.05). The negative reserve of NBT eosinophils in the sputum as a 
test to verify EPBA showed the following diagnostic values: specificity – 83.3%, predicted value of a positive result – 
95.6%. IL-5 content in the blood serum of children with EPBA was 5.99 ± 1.74 ng/ml, in patients of group ІІ  – only 
1.99 ± 0.49 ng/ml (P < 0.05). Eosinophil cationic protein (ЕСР) in the sputum of patients of group I reached 2.72 ± 
0.35 ng/ml, and in the comparison group – only 1.74 ± 0.34 ng/ml (P < 0.05), when the content of ECP in sputum was 
>1.0 ng/ml the risk of EPBA showed a statistically significant increase: OR = 4.13, RR = 2.02, and AR – 0.34. 
The efficacy of the standardized basic anti-inflammatory therapy in patients of clinical group I was higher as compared 
to the children with the signs of NPBA, which was illustrated by the reduced risk of inadequate control of the disease: 
the index of absolute risk decrease was 31.7%, relative risk – 57.1% with necessary minimal number of patients – 1.75.  
Keywords: NBT-test; airway inflammation; eosinophil cationic protein; asthma  
 
Introduction  
 
Nowadays bronchial asthma in children is considered as a 
disease characterized by chronic inflammation of the bronchi, in the 
development of which various cells and cellular elements play a 
certain role (Global Strategy for Asthma Management and 
Prevention, 2016). In case of antigenic stimulation, primary effector 
cells (epithelial cells of the respiratory tract, mast cells, 
macrophages) bound with IgE are considered to release mediators 
of inflammation resulting in the development of an inflammatory 
reaction both of an immediate and late type. The main mediators 
evaluating acute phase of inflammation are interleukins, tumor-α 
necrosis factor, interferon-γ, activating a range of immunological 
reactions and promoting the release of histamine, leukotrienes, 
eosinophil hemotaxis factors, neutrophils and other mediators of 
inflammation into the peripheral circulation (Chatila et al., 2008). 
Acidophilic leukocytes described more than 120 years ago by Paul 
Ehrlich and named as “eosinophils” were and still remain a matter 
of high scientific interest in different branches of medicine. Since 
that  time asthma and helminthiasis and acute anaphylaxis have 
been associated with them and eosinophilia of the peripheral blood 
as a pathogenic syndrome of asthma was examined at the very 
beginning of the XX century. However, the role of these cells in 
occurrence of epithelial injury and other phenomena of late phase 
allergic inflammation was defined only during the last decade of the 
last century (Beasley et al., 1989). Eosinophils constitute from 1% 
to 4% of the total number of leukocytes (120–350 cells/mm2). They 
are of a specific granularity approximately 200 granules per cell. 
The granules contain alkaline proteins, the majority of them being 
large principal protein, eosinophil cationic protein, eosinophil 
peroxidase, and eosinophil neurotoxin (Motojima et al., 1989). 
Proinflammatory properties have been found in eosinophils due to 
those substances which are characterized by cytotoxicity and aid 
stimulation of mast cells and basophils degranulation, and therefore 
detection of the content of cationic proteins and peroxidase can be 
indicative of the degree of activation of the major proinflammatory 
cells of an allergic inflammation, and indirectly – of severity of this 
inflammatory process. At the same time, eosinophils are mainly 
tissue cells and this fact complicates the study of their functional 
peculiarities (Novitskiy et al., 2006).  
In literary sources the bulk of attention has been paid to the 
detection of cytotoxic substances of eosinophil granulocytes in the 
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peripheral blood and their relation to the severity of disorders in the 
general condition of patients suffering from allergic processes 
(Litvinova et al., 2006). Considering the leading role of eosinophils 
in allergic inflammation which occurs with bronchial asthma 
(Pavord, 2013), the study of the diagnostic and prognostic value of 
various indices of eosinophil granulocyte activity remains a high 
priority task for allergology (Jacobsen et al., 2014). At the same 
time, the highest informational value undoubtedly attaches to the 
above mentioned markers of acidophilic leukocytes activity located 
directly in the “shock” organ of bronchial asthma – in the 
respiratory tract. Literary data concerning the use of changes of 
eosinophil metabolic activity to improve the control of bronchial 
asthma (BA) in children are sparse and contradictory. Some of 
these sources contain sufficient diagnostic value of the given 
inflammatometric markers (Madison, 2000), while other resear-
chers are convinced that the use of indices of eosinophil leukocyte 
activity in the blood alone is a test with insufficient information 
value to confirm the presence of BA in children (Kato et al., 2006). 
However, an increased number of eosinophils in the peripheral 
blood and respiratory tract, increased content of cationic proteins in 
the blood serum and shock-organs of patients with allergic patho-
logy are considered by a number of authors as markers of unfavou-
rable prognosis of bronchial-obstructive conditions in children (Jens 
et al., 2015).  
This article aims at improving the management of bronchial 
asthma in children by examining the peculiarities and diagnostic 
value of reaction markers of eosinophil granulocytes in the sputum 
and peripheral blood of patients with signs of eosinophil and non-
eosinophil phenotypes of the disease.  
 
Materials and methods  
 
A cohort of 118 school-age children suffering from BA was 
examined during a period free from attacks at the Pulmo-Allergo-
logical Department, Regional Children’s Municipal Hospital, 
Chernivtsi, adhering to the principles of bioethics by means of the 
simple random sample method. Two clinical groups were formed 
based on the results of cytomorphological examination of sputum. 
Group I (main) included 61 schoolchildren (77.1% among them 
were boys) with the signs of the eosinophil phenotype (EP) of 
asthma detected by the character of bronchial inflammation when 
eosinophil granulocytes were present in the sputum at a level of  
≥3%. Group II  (comparison) included 57 patients (52.6% boys, 
P < 0.05) with a lower number of eosinophils in the sputum, and 
due to this fact the non-eosinophil variant of bronchial inflam-
matory response was detected in those children, and thus – non-
eosinophil phenotype (NP) of BA. The value of  relative content of 
eosinophils in the sputum of group I of patients was 13.3 ± 1.8%, 
and in group II  – 1.94 ± 0.48% (P < 0.001), which was indicative 
of the correct formation of the comparison groups.  
The average age of the representatives of groups I and II was 
11.9 ± 0.42 and 11.04 ± 0.39 years respectively (P > 0.05). Differen-
ces between the groups in the age of first onset of BA were not found; 
thus in group I asthma made its first onset at the age of 2.2 ± 0.11, and 
in the comparison group this index was 2.1 ± 0.12 (P > 0.05).  
In group I an intermittent course of eosinophil phenotype of 
bronchial asthma (EPBA) was registered in 2 cases (3.3%), mild 
persistence – in 10 children (16.4%), and in group II (the compa-
rison group) – in 5 patients (8.8%) and only in 6 patients (10.5%, 
P > 0.05) respectively. The atopic form prevailed among the 
representatives of group II (59.6% against 40.0%, P < 0.05), and the 
mixed form was found in patients with EPBA (60.0% against 
40.4%, P < 0.05). The groups were compared by the main clinical 
signs, and certain evident differences between the groups did not 
affect the results obtained but only emphasized the phenotype 
heterogeneity of the disease and the presence of different phenotype 
variants in sick children.  
The control of the disease was evaluated by means of a 
questionnaire containing clinical-spirometrical findings according 
to which a value of 10 and lower reflected a controlled course of 
BA, 11–16 a partially controlled course of the disease, higher than 
17 indicated an uncontrolled variant of BA (Boulet et al., 2002). 
Quantitative and qualitative cytological content of the sediment was 
detected in sputum of patients, the results were considered to be a 
group-forming sign: when >3% eosinophil granulocytes were found 
in the sputum the patients were included into group I, patients with 
a lower number were placed in clinical group II ( the comparison 
group). At the same time, the fluid fraction above the sediment 
obtained after sputum was centrifuged and the content in this of 
human eosinophil cationic protein (ECP) was detected by means of 
ELISA-method according to the technique worked out by the 
producer and using reagents Aviscera Bioscience, Inc. (USA). ЕСР 
reflected cytotoxic activity of sputum eosinophils, and its average 
content in the cohort of all the patients was 2.28 ± 2.2 ng/ml (from 0 
to maximum value – 9.2 ng/ml).  
The markers of oxygen-dependent metabolism of eosinophil 
granulocytes in the blood and sputum were studied using the data of 
the spontaneous and stimulated NBT-test (B. H. Park’s method in 
modification of Klimov et al. (1988), nitroblue tetrazolium test). 
The reserve of microbicidal ability of these cells was calculated as 
the difference between the results of the spontaneous and the 
stimulated NBT-test. Phagocytic function of acidophilic leukocytes 
in the peripheral blood and sputum was detected by means of 
E. F. Chernushenko’s method.  
Interleukin-5 (ІL-5) content, which is directly connected with 
eosinophil functions, was examined in the blood serum by means of 
the solid-phase immune-enzymatic method using the reagents “IFA-
Best” (RF) according to the recommendations of the producer.  
The results obtained were analyzed by means of the computer 
package Statistica 6.0 (StatSoft Inc., USA) using parametric and 
non-parametric methods of calculation and by means of clinical-
epidemiological analysis.  
 
Results and discussion  
 
The study demonstrated that in the cohort of the examined 
patients the eosinophil phenotype of bronchial asthma (EPBA) was 
found 1.5 times more frequently among the boys, while the non-
eosinophil phenotype of bronchial asthma (NPBA) was detected 
more frequently among the girls. Therefore, the male gender was 
associated with an increased risk of EPBA: odds ratio (OR) index 
was 7.3 (95% CІ: 1.69–8.23), relative risk (RR) – 1.63 (95% CІ: 
1.02–2.59), attributive risk (АR) – 0.3. Post-test probability (PP+) 
of presence of eosinophil variant of bronchitis among boys 
increased by 16.6%, and among girls (PP–) decreased by 15.1%.  
Persistence of BA of moderate severity occurred in every 
second (50.9%) representative of clinical group II, and among the 
patients with EPBA it was in 1.5 times less (Р = 0.05). By contrast, 
the severe course prevailed significantly among the patients of the 
clinical group I. The indices of asthma control during initial exami-
nation did not differ among the patients with alternative phenotypes 
of BA, and on completion of the 3rd month of the basic therapy 
they appeared to be significantly worse among patients with NPBA. 
Thus, the average score by clinical-instrumental scale to evaluate 
asthma before the course of treatment in group I was 18.16 ± 1.03, 
and in group II – 18.17 ± 1.28 (P > 0.05). At the same time an 
uncontrolled course of the disease was registered in 55.4% of the 
patients in the survey with signs of EPBA, and in group II – in 
52.8% cases (P > 0.05).  
There was a tendency to the reduction of the absolute and 
relative number of eosinophils in the peripheral blood of patients in 
clinical group I. This may well indicate migration of those effector 
cells into the “target organ”. The average index of relative content 
of eosinophils in the peripheral blood among the representatives of 
group I was 5.82 ± 0.63%, and in children with the signs of NPBA – 
6.02 ± 0.74% (P > 0.05), and average indices in both groups of 
absolute eosinophil number (AEN) in the blood were 0.37 ± 0.04 
and 0.41 ± 0.05 respectively (P > 0.05). Considering AEN index 
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≥0.5 as a paraclinical marker of blood eosinophilia, it was found 
that in group I it was registered in 27.9% of the patients, and in 
group II ( the comparison ) – in 35.1% (P > 0.05). Therefore, the 
index of AEN ≥ 0.5 was associated with an inceased risk of NPBA: 
OR = 1.4 (95% CІ: 0.69–3.05), RR = 1.2 (95% CІ: 0.69–2.02), 
АR = 0.08. At the same time, post-test probability (PP+) of 
presence of the non-eosinophil variant of bronchitis increased only 
by 5.7%, and with lower values of AEN (PP–) it decreased only by 
2.6%. Statistically valuable differences in the indices of oxygen-
dependence microbicidal capacity of eosinophils in the peripheral 
blood and sputum of children with alternative phenotypes of BA 
were not found (Table 1). Table 1 presents the results of the NBT-
test of eosinophil granulocytes (%) in the blood and sputum in 
groups I and II of patients. Thus, the lowest reserve of oxygen-
dependent microbicidal capacity of eosinophils in sputum was 
found in patients with EPBA signs, which was indicative of their 
leading role in allergic inflammation of the respiratory tract. Negative 
values of the reserve of NBT-test indices of eosinophils in sputum 
(as the difference between stimulated and spontaneous results) increa-
sed the risk (OR) of EPBA presence by 6.1 times (95% CІ: 0.65–
57.15), at the same time RR was 1.2 (95% CІ: 0.20–7.47), and AR – 
0.17. The negative reserve of NBT eosinophils in sputum as the test 
to verify EPBA showed the following diagnostic values: 
specificity – 83.3% (95% CІ: 35.9–99.9), predicted value of a 
positive result – 95.6% (95% CІ: 78.1–99.9), spread – 86.9% (95% 
CІ: 73.7–95.1), accuracy – 58.7% (95% CІ: 43.2–73.0).  
The indices of phagocytic function of eosinophil granulocytes 
in the peripheral blood and sputum in patients with alternative 
phenotypes of BA also emphasized the role of these effector cells in 
allergic inflammation of the respiratory tract (Table 2).  
Table 1 
Markers of oxygen-dependent metabolism of eosinophils in the blood and sputum in children with eosinophil phenotype of bronchial asthma  
NBT spontaneous, % NBT stimulated, % Indices  blood sputum blood sputum 
Eosinophil phenotype of bronchial asthma 17.6 ± 2.13 15.6 ± 4.58 18.8 ± 0.97 15.7 ± 3.86 
Non-eosinophil phenotype of bronchial asthma 17.3 ± 1.26 20.2 ± 6.25 19.2 ± 1.34 22.0 ± 6.94 
P ˃0.05 ˃0.05 ˃0.05 ˃0.05 
 
Table 2 
Indices of phagocytic function of eosinophils in the blood and sputum in children from the clinical groups of comparison  
Phagocytic activity, % Phagocytic number, standard units Indices  blood sputum blood sputum 
Eosinophil phenotype of bronchial asthma 68.7 ± 6.36 62.1 ± 2.34 3.24 ± 0.29 3.02 ± 0.53 
Non-eosinophil phenotype of bronchial asthma 73.6 ± 6.03 26.7 ± 2.54 4.52 ± 0.53 0.40 ± 0.05 
P ˃0.05 ˂0.05 ˃0.05 ˂0.05 
 
The presence of statistically important differences in the 
markers of phagocytic function of eosinophils in the sputum of 
children correlated with preliminary suggestions concerning active 
involvement of these cells into the inflammatory process of the 
bronchi, which was emphasized by an increased content of IL-5 in 
the blood serum in the representatives of clinical group I. Thus, IL-5 
content in the blood serum of children with EPBA was 5.99 ± 
1.74 ng/ml, in patients of group II it was only 1.99 ± 0.49 ng/ml 
(P < 0.05). When the index of IL-5 in the blood was more than 
2.0 ng/ml the risk of EPBA increased: OR = 2.5 (95% CІ: 0.49–
12.64), RR = 1.4 (95% CІ: 0.61–3.34), and AR – 0.2. The indices 
of diagnostic value of this paraclinical test in verification of EPBA 
appeared to be rather modest: sensitivity – 62.5% (95% CІ: 35.4–
84.8), specificity – 60.0% (95% CІ: 26.2–87.8), predicted value of a 
positive result – 71.4% (95% CІ: 41.9–91.6), spread – 61.5% (95% 
CІ: 40.6–79.8), accuracy – 61.5% (95% CІ: 40.6–79.8). When IL-5 
in the blood serum was >2.0 ng/ml post-test probability of EPBA 
increased by 11.0%, and in case of a negative result of the test it 
was 11.5% lower.  
Eosinophil cationic protein (ЕСР), detected in the sputum fluid 
above the sediment as a marker of intensified degranulation of cells 
in the bronchi proved the presence of mainly eosinophil-mediated 
inflammation of the respiratory tract of patients with EPBA. Thus, 
the average content of this cytotoxic mediator in sputum of patients 
of group I reached 2.72 ± 0.35 ng/ml, and in the comparison 
group – only 1.74 ± 0.34 ng/ml (P < 0.05). When the content of 
ECP in sputum was >1.0 ng/ml the risk of eosinophil inflammation 
of the respiratory tract increased significantly: OR = 4.1 (95% CІ: 
1.5–11.2), RR = 2.0 (95% CІ: 1.4–3.0), and AR – 0.34. This 
paraclinical index as a marker of EPBA possessed the following 
diagnostic value: sensitivity – 78.6% (95% CІ: 63.2–89.7), 
specificity – 52.9% (95% CІ: 35.1–70.2), spread – 55.3% (95% CІ: 
43.4–66.7), accuracy – 67.1% (95% CІ: 55.4–77.5). With the above 
mentioned ECP content in the sputum post-test probability of 
EPAB presence increased by 12.5%, and in case of a negative result 
of the test it decreased by 21.2%.  
In our opinion, these results facilitate the verification of EPBA 
as they make it possible to differentiate the choice of medicines for 
the basic treatment of BA. On completion of the course of anti-
inflammatory therapy the average score in the questionnaire 
containing clinical-spirometrical findings in groups I and II was 
12.22 ± 1.34 and 14.71 ± 1.38 (P > 0.05) respectively, although a 
controlled course was found in 55.6% of patients with the eosinophil 
variant and only in 23.8% of the children with NPBA (P < 0.05). 
Therefore, the efficacy of the standardized (Order of the Ministry of 
Public Health of Ukraine № 868, 2013) basic anti-inflammatory 
therapy in patients of clinical group I was higher in comparison to 
the children with the signs of NPBA, which was illustrated by the 
reduced risk of inadequate control of the disease: the index of 
absolute risk decrease (ARD) was 31.8%, relative risk (RR) – 
57.1% with necessary minimal number of patients (NMNP) – 1.75.  
We have shown that application of markers of inflammatory 
response of the body such as eosinophils in the blood and sputum, 
indices NBT-test blood granulocytes, intracellular and extracellular 
content of cationic proteins in patients with asthma is highly 
sensitive to the nature of inflammation in the airways, which 
coincides with the literature (Wilson et al., 2000; Shirai et al., 2006; 
Broide, 2008; Johansson et al., 2008). For instance, we found that a 
severe course had a high probability of prevailing in patients with 
the eosinophilic phenotype of asthma compared to patients with 
neutrophilic inflammation of the airways. However, the literature 
mentions the severe course of bronchial asthma  as being due to the 
presence of neutrophil inflammation of the bronchi (Gibson et al., 
1999; Mann et al., 2006), although data on the nature of the 
relationship inflammation of the bronchi to the severity of the 
disease remain controversial (Li et al., 2003; Kikuchi et al., 2005). 
In particular, according to the literature, an elevated relative content 
of eosinophilic granulocytes in sputum of patients with eosinophil-
mediated type of disease is considered a marker of efficacy of anti-
inflammatory therapy, which was confirmed in our study, given the 
increase in the number of patients with a controlled disease course 
after a course of basic anti-inflammatory therapy. The effectiveness 
of standardized basic anti-inflammatory therapy in patients with the 
eosinophilic phenotype of asthma was significantly higher compa-
red with children who showed signs of the neutrophil phenotype, 
emphasizing the idea that the increase in the number of neutrophils 
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in the airways was registered in late phase allergic reactions in 
patients with so-called "fateful" and "nocturnal asthma", as well as 
severe forms of asthma (Wenzel, 2003; Kamath et al., 2005; Haldar 
et al., 2007).  
 
Conclusions  
 
The chances of developing eosinophil phenotype of asthma are 
greater in the following cases: with males (7.3 times), negative 
reserve of NBT-test of eosinophils in the sputum (6.1 times), IL-5 
content in the blood serum over 2.0 ng/ml (by 2.5 times) and 
eosinophil cationic protein content in the sputum over 1.0 ng/ml (by 
4.1 times). The highest specificity in verifying eosinophil inflam-
mation of the bronchi occurred with the negative reserve of the 
NBT-test of eosinophils in the sputum (83.3%), and the highest 
sensitivity in its detection – the content of ECP over 1.0 ng/ml 
(78.6%). Consideration of the character of a local inflammatory 
process in the bronchi enhances the efficacy of the basic therapy of 
bronchial asthma by 57.1% with its eosinophil phenotype less than 
in every second patient.  
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